Viking Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced positive top-line results from a 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C). The study successfully achieved its…